Leap Therapeutics Announces Completion of Enrollment in Randomized Controlled Part C of the DisTinGuish Study of DKN-01 for the Treatment of Gastric Cancer Patients ...Middle East

CAMBRIDGE, Mass. , Jan. 2, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that enrollment has been completed in the randomized controlled Part C of the DisTinGuish study...

Hence then, the article about leap therapeutics announces completion of enrollment in randomized controlled part c of the distinguish study of dkn 01 for the treatment of gastric cancer patients was published today ( Tuesday 02/01/2024 - 03:04 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Leap Therapeutics Announces Completion of Enrollment in Randomized Controlled Part C of the DisTinGuish Study of DKN-01 for the Treatment of Gastric Cancer Patients )

Also on site :

• From collapse fears to resilience: How Russia reshaped its economy by the end of 2025
• Russian MOD shows map of Ukrainian drone attack on Putin’s residence
• Advantech Unveils Next-Generation Edge AI Compute Solutions Powered by Qualcomm Dragonwing IQ-X Series